An immunostaining method includes an irradiation process in which a specimen, which includes a target molecule including an electron donor, an antibody that is bound to the target molecule and that includes a generating agent for generating active species when irradiated with a first excitation light, and a pigment compound, is irradiated with the first excitation light; and in which the pigment compound and the electron donor are bound due to the active species generated from the generating agent when irradiated with the first excitation light.

An immunostaining method includes an irradiation process in which a specimen, which includes a target molecule including an electron donor, an antibody that is bound to the target molecule and that includes a generating agent for generating active species when irradiated with a first excitation light, and a pigment compound, is irradiated with the first excitation light; and in which the pigment compound and the electron donor are bound due to the active species generated from the generating agent when irradiated with the first excitation light.

The technology provided herein relates to multiplex methods and kits for detecting different analytes in a sample in parallel by sequential signal-encoding of said analytes, as well as in vitro methods for screening, identifying and/or testing a substance and/or drug and in vitro methods for diagnosis of a disease, and an optical multiplexing system.

Devices and methods for the deposition of reagents onto cells or tissue samples are disclosed. Also disclosed are reagent compositions suitable for dispensing via a droplet-on-demand system.

The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag.sup.1+, Ba.sup.2+, Pb.sup.2+, Gd.sup.3+ and Bi.sup.3+) and one or more hematein ligand(s). In particular, the invention relates to the use of the complexes as ex vivo contrast agents for a computed tomography scanning of a biological sample. Moreover, the invention relates to specific ex vivo methods for investigating a biological sample by means of computed tomography scanning methods, wherein the method comprises staining the biological sample with a solution comprising one or more of the complex(es); or wherein the method comprises staining the biological sample with a staining solution comprising hematein, and separately contacting the biological sample with one or more staining solution(s) comprising one or more heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag.sup.1+, Ba.sup.2+, Pb.sup.2+, Gd.sup.3+ and Bi.sup.3+).

The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag.sup.1+, Ba.sup.2+, Pb.sup.2+, Gd.sup.3+ and Bi.sup.3+) and one or more hematein ligand(s). In particular, the invention relates to the use of the complexes as ex vivo contrast agents for a computed tomography scanning of a biological sample. Moreover, the invention relates to specific ex vivo methods for investigating a biological sample by means of computed tomography scanning methods, wherein the method comprises staining the biological sample with a solution comprising one or more of the complex(es); or wherein the method comprises staining the biological sample with a staining solution comprising hematein, and separately contacting the biological sample with one or more staining solution(s) comprising one or more heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag.sup.1+, Ba.sup.2+, Pb.sup.2+, Gd.sup.3+ and Bi.sup.3+).

The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

Provided herein are methods for preparing biological samples for spatial proteomic analysis, methods of determining a location of a protein analyte in a biological sample, and methods of determining a location of a protein analyte and a nucleic acid analyte in a biological sample.

Provided herein are methods for preparing biological samples for spatial proteomic analysis, methods of determining a location of a protein analyte in a biological sample, and methods of determining a location of a protein analyte and a nucleic acid analyte in a biological sample.